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Adrenomedullin (AM) is a potent vasodilator peptide in plasma at
picomolar levels. Polymorphisms in the human AM gene have been
associated with genetic predisposition to diabetic nephropathy
and proteinuria with essential hypertension, and numerous studies
have demonstrated that endogenous AM plays a role in protecting
the heart and kidneys from fibrosis resulting from cardiovascular
disease. Elevated plasma levels of AM are associated with preg-
nancy and sepsis and with cardiovascular stress and hypertension.
However, there are no reports of the effects of genetic differences
in the expression of the endogenous AM gene and of gender on
blood pressure in these circumstances or on the pathological
changes accompanying hypertension. To address these questions,
we have generated mice having genetically controlled levels of AM
mRNA ranging from 50% to 140% of wild-type levels. These
modest changes in AM gene expression have no effect on basal
blood pressure. Although pregnancy and sepsis increase plasma
AM levels, genetically reducing AM production does not affect the
transient hypotension that occurs during normal pregnancy or that
is induced by treatment with lipopolysaccharide. Nor does the
reduction of AM affect chronic hypertension caused by a renin
transgene. However, 50% normal expression of AM enhances
cardiac hypertrophy and renal damage in male, but not female,
mice with a renin transgene. These observations suggest that the
effect of gender on the role of AM in counteracting cardiovascular
damage in humans merits careful evaluation.
cardiovascular  pregnancy  cardiac hypertrophy  renal fibrosis 
gene targeting
Adrenomedullin (AM) is a 52-aa peptide vasodilator whichcirculates in the plasma as a protein-bound hormone and
can influence many biological processes (1). The gene coding for
AM is widely expressed throughout the body, most highly in
endothelial cells and vascular smooth muscle cells (2, 3). Con-
sequently, highly vascularized tissues, such as the placenta, lung,
heart, and kidney cause elevated plasma AM levels when their
secretion of AM peptide is stimulated by conditions such as
pregnancy, sepsis, and cardiovascular disease or by inflamma-
tory cytokines or hypoxia.
AM is most widely known for its vasodilatory properties (4).
Bolus injection or infusion of AM in humans (5–10) and in
several animal species (11–17) causes prolonged, dose-
dependent vasorelaxation and hypotension. Yet the dose, route,
and duration of exogenous administration required to elicit a
systemic effect on blood pressure (BP) varies widely among
published studies (8–10). Moreover, it is possible that bolus
infusions of the unbound peptide may not accurately replicate
the functions of the endogenous protein-bound peptide. Con-
sequently, it is important to determine whether modest changes
in expression of the endogenous AM gene affect the maintenance
of BP during health and disease.
Endogenous AM plays a role in protecting the heart and
kidneys from damage during cardiovascular stresses such as
hypertension and its associated cardiac hypertrophy, myocardial
infarction, heart failure, and atherosclerosis (18, 19). Thus,
comparisons between male mice with genetically reduced levels
of AM (AM/) and wild-type mice (AM/) have demon-
strated that the reduced level of endogenous AM increases the
damage to heart and renal tissue caused by aortic banding (20),
angiotensin II infusion (20, 21), bilateral renal artery clamping
(22), and atherosclerosis (23). However, although the expression
of the AM gene is transcriptionally regulated via estrogen-
responsive elements in its promoter region, the effects of dif-
ferent levels of AM in female mice have not been reported.
Moreover, in our previous studies, we have observed that the
regulation of AM gene expression during cardiovascular stress is
highly affected by gender (24, 25). Thus, it is clearly important
to determine the effects of differences in AM gene expression in
females, a point that is further emphasized by our demonstration
that female mice with only one copy of the gene have serious
reproductive defects involving abnormal implantation and fetal
growth restriction (26).
To study the effects of genetic differences in AM levels and
of gender, we have therefore generated mice with AM peptide
levels ranging from 50% to 140% of wild type , caused by
their having one (AM/), two (AM/), or three copies
(AM/Duplication) of the AM gene. The basal BPs were deter-
mined in male and female mice of these three genotypes under
normal conditions and in AM/ females during normal
pregnancy. To simulate the effects of sepsis, we administered
lipopolysaccharide (LPS) to AM/ males and females. To
evaluate the effects of chronic hypertension, we introduced a
renin transgene into the AM/ mice by breeding. We also
evaluated the effects of both reduced AM levels and of gender
on the degree of cardiovascular damage caused by the renin-
induced hypertension. These modest alterations of AM gene
expression do not affect basal BP or the changes in BP
accompanying normal pregnancy or after treatment with LPS
or consequent to chronic hypertension. However, male, but
not female, mice with 50% expression of AM develop greater
degrees of cardiac hypertrophy and renal damage when they
are hypertensive than do wild-type mice.
Results
Generation of AM Gene-Titration mice. To generate mice with
increased AM peptide levels that are within physiological ranges
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and genetically controlled, we used gene targeting to duplicate
the AM gene within its endogenous locus on mouse chromosome
7. The targeting vector (Fig. 1A) used the same regions of
homology as were previously used for generating mice with a
targeted deletion of the AM gene (27), but by using a different
arrangement of the DNA fragments, the cross-over event leads
to duplication of the AM gene. The second copy of the AM gene
on chromosome 7 contains 3.7 kb of 5 f lanking promoter
sequence. The duplicated allele was detected by Southern blot
analysis using a genomic probe fragment located outside the
areas of homology (Fig. 1B). Wild-type mice were designated
two-copy (AM/, one copy of the AM gene on each chromo-
some), heterozygote mice for the gene duplication were desig-
nated three-copy (AM/Duplication, one copy of the AM gene on
the wild-type chromosome and two copies on the targeted
chromosome), and homozygous mice were designated four-copy
(AMDuplication/Duplication, two copies of the AM gene on each
targeted chromosome).
Mice with only one copy of the AM gene have been described
(27) and were heterozygous for a targeted deletion of the AM
gene (AM/). These one-copy mice produce 50% wild-type
levels of AM mRNA and peptide.
To confirm that the series of AM gene-titration mice with
different copy numbers of the AM gene resulted in modest yet
physiologically relevant changes in AM gene expression, quan-
titative RT-PCR for AM was performed on total RNA isolated
from adult kidneys. As expected, and shown in Fig. 1C, AM
one-copy mice had approximately half the levels of AM RNA
compared with AM two-copy mice, whereas AM three-copy
mice had 120% more AM RNA than AM two-copy mice. AM
four-copy mice had 140% more AM RNA than AM two-copy
mice (data not shown). AM peptide radioimmunoassays were
performed on protein extracts from kidney and left ventricle and
showed a significant and dose-dependent increase in AM pep-
tide levels between the one-, two-, and three-copy mice (Fig. 1D).
Basal BP Is Unaffected by AM Gene Copy Number. To determine
whether modest, genetically induced changes in AM gene ex-
pression affect the basal BP of conscious, restrained animals,
BPs of the AM gene-titration mice were measured for 6 con-
secutive days by using a computerized tail cuff system. As shown
in Fig. 2A, we found no significant differences in the basal BPs
of male mice with one to four copies of the AM gene (one copy,
108  1; two-copy, 113  2; three-copy, 115  2; four-copy,
111  5 mmHg; P  0.07). Fig. 2B shows comparable results for
the female AM gene-titration mice (one-copy, 109  2; two-copy,
110  2; three-copy, 109  5; four-copy, 101  3 mmHg; P 
0.2). Taken together, the results in Fig. 2 demonstrate that
genetically controlled levels of AM peptide over the range of
50–140% wild-type levels has no effect on the basal BPs of
male or female mice.
Reduced AM Expression Does Not Affect the Transient Hypotension
During Pregnancy or After LPS Treatment. Because pregnancy and
sepsis cause the greatest increases in AM levels, and because
both conditions are accompanied with hypotension, we next
asked whether a genetic reduction in AM moderates this
hypotension.
Fig. 1. Generation of AM gene-titration mice. (A) Targeting strategy used to
generate mice with a duplication of the AM gene on chromosome 7. The
targeting vector consisted of regions of homology that flank the entire AM
gene so that all sequences between the endogenous 5 BamH1 site and 3 Sac
site were duplicated in the second copy. Primers to identify ES cells are labeled
P1, P2, and P3. (B) Southern blot of correctly targeted ES cells by using genomic
DNA digested with BamH1 and the probe sequence depicted in A. The
wild-type allele is 11 kb, and the targeted allele is 21 kb. (C) Levels of AM RNA
in kidney of one-, two-, and three-copy mice measured by quantitative RT-
PCR. (D) Levels of AM peptide in kidney of one-, two-, and three-copy mice
measured by RIA. (E) Levels of AM peptide in left ventricle (LV) of one-, two-,
and three-copy mice measured by RIA. A, AvrII; B, BamH1; Sp, Spe; X, Xba; S,
SacI. *, P  0.05 vs. one-copy; ***, P  0.001 vs. one-copy; †, P  0.05 vs.
two-copy. n  5 for each genotype in C–E. Error bars represent SEMs.
Fig. 2. Mean BPs are unaffected by AM gene copy number. (A) Mean BPs of
conscious AM gene-titration male mice measured by computerized tail cuff.
(B) Mean BPs of conscious AM gene-titration female mice measured by com-
puterized tail cuff.











To measure BPs during pregnancy, we used radio telemetry in
AM one-copy and wild-type female mice. This method allowed
for the continuous, uninterrupted monitoring of basal BP in
unrestrained and unanesthetized animals over a period of several
weeks. In agreement with the results from our tail-cuff studies,
we found no significant differences in basal BPs between wild-
type and AM one-copy mice before pregnancy (data not shown)
or at any time during pregnancy (Fig. 3A). Similar to humans,
both wild-type and AM one-copy female mice displayed a
characteristic drop in BP during midgestation (pregnancy day
7–10), which recovered to, but never exceeded the prepregnancy
BP levels by the end of gestation. Moreover, because AM
one-copy male mice were bred to AM one-copy female mice, we
can also conclude that the presence of AM-null embryos within
a litter does not influence maternal blood pressure during
pregnancy. Therefore, genetic reduction of AM by as much as
50% in mice does not affect the systemic changes in BP that
occur transiently during the course of a normal pregnancy.
To determine whether genetically reduced levels of AM affect
the degree of acute hypotension associated with septic shock,
telemetry was used to monitor the BPs of wild-type and AM
one-copy male mice that were injected i.p. with LPS to induce
septic shock. Some of the mice in this experiment were also
heterozygous for a renin transgene (RenTgMK, described be-
low), so that they had elevated BPs before induction of septic
shock. As shown in Fig. 3B, before injection of LPS, all mice
displayed normal diurnal circadian rhythms in BP. Injection of
LPS caused an immediate and dramatic fall in BP to 50–80
mmHg over 2–3 days. However, we found no significant differ-
ence in the overall drop in BP between AM two-copy and AM
one-copy mice. Therefore, genetic reduction of AM in mice has
no effect on the transient hypotension that occurs during in-
duced septic shock.
Reduced AM Expression Does Not Affect the Chronic Hypertension in
Mice Overexpressing Renin. To determine whether a reduction in
AM gene copy number can affect the development of hyperten-
sion caused by a genetic increase in renin production, we crossed
the AM one-copy mice to mice that carry a targeted insertion of
a transgene that expresses renin at high and constant levels from
the liver. A single copy of the transgene, RenTgMK, elevates
plasma renin levels and causes hypertension, cardiac hypertro-
phy, cardiovascular end-organ damage, and early death (25). Fig.
3C shows that, compared with wild-type mice, a single copy of
the RenTgMK transgene causes an increase in BP of 45 mmHg
(wild type, 108  9; AM two-copy:RenTgMK, 145  8 mmHg).
Reducing the copy number of the AM gene to one copy had no
significant effect on the hypertension induced by the RenTgMK
(AM one-copy:RenTgMK, 149  12 mmHg; P  0.77 compared
with AM two-copy:RenTgMK). Moreover, we again find no
significant differences in BPs between AM one-copy and wild-
type mice (AM one-copy, 112  3 mmHg; P  0.65 compared
with wild type). Similar results were obtained for female mice of
the same genotypes: wild type, 98  7 versus AM one-copy, 96 
5 mmHg (P  0.9); AM two-copy:RenTgMK, 139  6 versus
AM one-copy:RenTgMK, 133  5 mmHg (P  0.4). Therefore,
genetic reduction of endogenous AM in male or female mice has
no effect on the chronic hypertension that is induced by genetic
overexpression of a renin transgene.
Taken together, the data in Fig. 3 demonstrate that when
physiological conditions associated with elevated plasma AM
levels in humans (pregnancy, sepsis, and hypertension) are
reproduced in mice, the genetic reduction of AM has no effect
on BP.
Genetic Reduction of AM Exacerbates Cardiovascular Damage in Male,
but Not Female, Mice with Chronic Hypertension. Studies have
demonstrated that male mice heterozygous for a targeted
deletion of the AM gene are more susceptible than wild-type
mice to cardiac hypertrophy, fibrosis, and renal damage in-
duced by aortic constriction or infusion of angiotensin II.
However, female mice were not examined in these studies. To
determine whether gender affects the protective functions of
AM during cardiovascular disease, we characterized male and
female mice that were either wild type or heterozygous for the
AM gene deletion and either wild type or heterozygous for the
presence of the RenTgMK transgene. Fig. 4A shows that male
mice with only one copy of AM and the RenTgMK transgene
have a significantly greater degree of cardiac hypertrophy (as
measured by left ventricular-to-body weight ratio) compared
with male mice with two copies of the AM gene and the
Fig. 3. Physiologically induced changes in BP are unaffected by AM gene
copy number. (A) Mean arterial pressures (MAP) of wild-type (squares and
line) and AM one-copy (triangles and line) female mice during pregnancy,
measured by radiotelemetry. (B) Mean arterial pressures (MAP) of male AM
two-copy (thick lines) and one-copy mice (thin lines) that were either wild-
type (black) or targeted for the RenTgMK transgene (gray lines) before and
after injection of LPS, measured by radiotelemetry. (C) Mean BPs of male mice
that were wild type, AM two-copy (i.e., wild type):RenTgMK, AM one-copy, or
AM one-copy:RenTgMK. In all cases, there were no significant effects of AM
gene copy number on BP changes.
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RenTgMK transgene. In contrast, in female mice, there was no
significant increase in the degree of cardiac hypertrophy between
AM one- and two-copy animals that were heterozygous for the
RenTgMK transgene (Fig. 4B) compared with their nontrans-
genic sisters. Histological characterization of the left ventricles
from the mice revealed similar degrees of coronary artery
fibrosis independent of gender and across all genotypes (Fig.
4C). Nevertheless, when we used computerized morphometry to
measure the cross-sectional area of the hypertrophied myocytes,
we found that whereas male AM one-copy:RenTgMK mice had
significantly larger myocytes than AM two-copy:RenTgMK
mice, female mice of comparable genotypes did not (Fig. 4D).
Thus the male, but not the female, mice develop greater cardiac
hypertrophy as a result of chronic hypertension when they have
one copy of the AM gene compared with gender-matched
animals with two copies of the AM gene.
A similar pattern of gender differences also emerged with
respect to renal damage: renal damage in male, but not female,
RenTgMK mice was increased by genetic reduction of AM.
Thus, as shown in Fig. 4E, the degree of glomerular sclerosis and
presence of proteinacious casts was markedly worse in male AM
one-copy:RenTgMK mice compared with either male AM two-
copy:RenTgMK mice or female mice. Histological scoring of
renal damage revealed that the reduction of AM copy number
did not significantly exacerbate the renal damage in female mice
but caused a significant worsening of renal disease in male mice
(Fig. 4F). Consistent with increased renal fibrosis in male AM
one-copy:RenTgMK mice, we found a significant increase in the
gene expression of the fibrotic marker transforming growth
factor  in the kidneys of these mice compared with male AM
two-copy:RenTgMK controls. In contrast, the gene expression
Fig. 4. AM one-copy male, but not female, mice suffer greater degree of cardiac hypertrophy in response to RenTgMK than wild-type mice. (A) Left ventricular
(LV) to body weight (BW) ratio of 6- to 8-month-old male mice wild type, AM two-copy:RenTgMK, AM one-copy, or AM one-copy:RenTgMK showing a significant
effect of reduced AM on left ventricular hypertrophy. (B) Left ventricular (LV) to body weight (BW) ratio of 6- to 8-month-old female mice wild type, AM
two-copy:RenTgMK, AM one-copy, or AM one-copy:RenTgMK showing no significant effect of reduced AM on left ventricular hypertrophy. (C) Masson’s
trichrome staining of left ventricle shows coronary vessel fibrosis and enlarged myocytes. (D) Morphometric analysis of myocyte cross-sectional area shows that,
compared with gender matched AM two-copy:RenTgMK control mice, male AM one-copy:RenTgMK mice have significantly larger myocytes than female AM
one-copy:RenTgMK mice. (E) Masson’s trichrome staining of kidney shows renal vascular fibrosis, glomerular sclerosis, and infiltration of immune cells that is more
severe in male mice. Proteinacious casts (arrows) were abundant in AM one-copy:RenTgMK male mice, occasionally observed in AM two-copy:RenTgMK male
mice but absent in female mice of similar age and genotype. (F) Renal damage induced by RenTgMK was scored by using arbitrary units for the severity of
glomerular sclerosis, vascular fibrosis, interstitial fibrosis, and proteinacous casts. AM one-copy:RenTgMK male, but not AM one-copy:RenTgMK female, mice
had significantly greater renal damage than age and gender-matched AM two-copy:RenTgMK mice.











levels of transforming growth factor  in the kidney were
unaffected by the copy number of the AM gene in female mice
(data not shown).
When we used the Fisher method (28) to test for the combined
significance of these related but independent measures of cardio-
vascular damage, we found a highly significant overall difference in
the severity of cardiovascular disease in male AM one-
copy:RenTgMK mice (P  0.02) but not in female AM one-
copy:RenTgMK mice (P  0.5), compared with gender-matched
AM two-copy:RenTgMK control animals. Taken together, the
results of Fig. 4 demonstrate that a reduction in endogenous levels
of AM gene expression increases hypertension-related cardiovas-
cular damage in male, but not in female, mice.
Discussion
We describe the generation of mice with a targeted duplication
of the AM gene. When combined with mice that are heterozy-
gous for a targeted deletion of the AM gene, these mice provide
a genetically controlled series of animals with variations in AM
gene expression that range from 50–140% wild-type levels.
This ‘‘gene titration’’ is therefore useful for modeling any modest
variations in AM gene expression that may occur in the human
population because of genetic polymorphisms of the AM gene
(29, 30). As opposed to conventional transgenic approaches
where a tissue-specific promoter drives the expression of a
randomly inserted transgene, the gene-titration model offers the
advantage of retaining the normal location of the duplicated
gene, driven by the endogenous promoter.
Plasma levels of AM rise dramatically in humans with a wide
variety of cardiovascular conditions, and it has been hypothe-
sized that elevated plasma AM may help regulate the changes in
BP that accompany pregnancy, sepsis, and cardiovascular stress.
Our experiments bear on this hypothesis because they test the
effects of reduced AM gene expression on both transient hypo-
tenstion and chronic hypertension.
Our results prove to be remarkably consistent and show that
modest alterations in AM gene expression, either decreased or
increased, have no effect on the basal BPs of male or female mice.
This finding may be somewhat surprising given the wealth of
information showing that AM infusions can elicit long-lasting
depressor effects in several species of experimental animals (12, 31)
and in humans (10). Shindo et al. (32) have also generated a line of
mice with targeted deletion of the AM gene and reported that
conscious and unrestrained heterozygous mice had elevated BPs
but, in a later study, found no significant differences in BPs between
unanesthetized, wild-type, and AM heterozygous mice by using a
tail cuff method (21). It is therefore likely that the observed
differences in BP in their first study (32) may have been due to
different methods of BP measurement (33). A third group gener-
ated another line of AM gene-targeted mice and, consistent with
our findings, has found no differences in basal BPs of AM het-
erozygous mice measured by either indirect tail cuff or direct
catheterization of the carotid artery (34). Although AM four-copy
mice with 140% wild-type expression of AM do not have de-
creased BP, transgenic mice with 8-fold overexpression of AM in
the vasculature and 2.3-fold increase in plasma AM have lower BP
that is normalized to wild-type levels when the mice are treated with
a NOS inhibitor (23, 35). Thus, our analysis of AM gene-titration
mice is consistent with previous studies and leads to the conclusion
that modest alteration in endogenous AM gene expression does not
affect basal BP in mice.
The action of AM peptide as a protective factor in the heart
and kidney has been well established in male mice, but there have
been no comparable studies in female mice. In our previous
studies we have observed that changes in AM gene expression
induced by several types of cardiovascular stress differ signifi-
cantly in the two sexes (24, 25). For this reason, and because the
AM gene is highly regulated by estrogen (36, 37), and because the
AM one-copy female mice display profound reproductive de-
fects (26), we suspected the established cardioprotective effects
of endogenous AM might also be gender-dependent. Our results
are consistent with previous studies in showing that the reduced
levels of AM in AM one-copy male mice increase the cardio-
vascular damage induced by chronic hypertension. In marked
contrast, in female mice, the degree of cardiovascular damage
induced by the RenTgMK transgene is unaffected by the reduc-
tion in AM levels. Recently, Pearson et al. (38) found that
estrogen and testosterone have different effects on the amount
of AM secreted from angiotensin II-stimulated human endo-
thelial cells, suggesting that an interplay between sex steroids and
angiotensin II may account for the gender differences observed
in our study. These findings clearly demonstrate that the tissue
damage caused by hypertension is enhanced in male, but not in
female, mice when AM levels are decreased. Our study suggests
that the effect of gender on the beneficial role of AM in
counteracting cardiovascular damage in the human population
merits careful evaluation.
Materials and Methods
Additional information on materials and methods is available in
supporting information (SI) Text. Standard gene-targeting meth-
ods were used to generate ES cells and mice with a targeted
duplication of the AM gene (39). Male chimeric mice that
transmitted the targeted allele were bred to 129S6/SvEv females
to establish isogenic lines.
BPs were measured on unanesthetized, restrained mice by a
computerized tail-cuff system, as described (40). Continuous
recording of the BPs of unanesthetized, unrestrained animals
was performed by radio telemetry.
To genetically induce hypertension and cardiac hypertrophy in
the AM one-copy mice, heterozygous RenTgMK (25, 41, 42)
mice were crossed to heterozygous AM one-copy mice. All mice
were maintained on an isogenic SvEv129/S6 genetic background
and were 6–8 months of age at the time of killing.
Experimental animals were 6–8 months of age and main-
tained on an isogenic 129S6/SvEv background. Control animals
were wild-type, age- and gender-matched littermates. All exper-
iments were approved by the Institutional Animal Care and Use
Committee of the University of North Carolina at Chapel Hill.
Statistical analyses for multiple comparisons were performed
with one-way ANOVA using JMP Software (SAS Institute,
Cary, NC). In all figures, error bars represent standard errors of
the mean.
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